172 related articles for article (PubMed ID: 20334914)
21. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
[TBL] [Abstract][Full Text] [Related]
22. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.
Makishima H; Jankowska AM; McDevitt MA; O'Keefe C; Dujardin S; Cazzolli H; Przychodzen B; Prince C; Nicoll J; Siddaiah H; Shaik M; Szpurka H; Hsi E; Advani A; Paquette R; Maciejewski JP
Blood; 2011 May; 117(21):e198-206. PubMed ID: 21346257
[TBL] [Abstract][Full Text] [Related]
23. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
24. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS).
Boissinot M; Garand R; Hamidou M; Hermouet S
Blood; 2006 Sep; 108(5):1781-2. PubMed ID: 16926301
[No Abstract] [Full Text] [Related]
25. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Huls G; Mulder AB; Rosati S; van de Loosdrecht AA; Vellenga E; de Wolf JT
Blood; 2010 Jul; 116(2):180-2. PubMed ID: 20194893
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R
Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856
[TBL] [Abstract][Full Text] [Related]
27. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.
Abdel-Wahab O; Tefferi A; Levine RL
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1053-64. PubMed ID: 23009937
[TBL] [Abstract][Full Text] [Related]
28. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
29. Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis.
Lee MY; Jang S; Park CJ; Cho YU
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443589
[TBL] [Abstract][Full Text] [Related]
30. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J; Lippert E; Harutyunyan AS; Jeromin S; Zipperer E; Florensa L; Milosevic JD; Haferlach T; Germing U; Luño E; Schnittger S; Kralovics R; Girodon F
Leukemia; 2014 Jun; 28(6):1374-6. PubMed ID: 24476766
[No Abstract] [Full Text] [Related]
31. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
[TBL] [Abstract][Full Text] [Related]
32. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.
Visconte V; Rogers HJ; Singh J; Barnard J; Bupathi M; Traina F; McMahon J; Makishima H; Szpurka H; Jankowska A; Jerez A; Sekeres MA; Saunthararajah Y; Advani AS; Copelan E; Koseki H; Isono K; Padgett RA; Osman S; Koide K; O'Keefe C; Maciejewski JP; Tiu RV
Blood; 2012 Oct; 120(16):3173-86. PubMed ID: 22826563
[TBL] [Abstract][Full Text] [Related]
33. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
Raya JM; Arenillas L; Domingo A; Bellosillo B; Gutiérrez G; Luño E; Piñán MA; Barbón M; Pérez-Sirvent ML; Muruzábal MJ; Yánez L; García L; Lemes A; Navarro JT; Elosegi A; Cortés MA; Villegas A; Durán MA; Ardanaz M; Florensa L;
Int J Hematol; 2008 Nov; 88(4):387-395. PubMed ID: 18820995
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.
Cazzola M; Malcovati L
Hematology Am Soc Hematol Educ Program; 2015; 2015():19-25. PubMed ID: 26637696
[TBL] [Abstract][Full Text] [Related]
35. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Renneville A; Quesnel B; Charpentier A; Terriou L; Crinquette A; Laï JL; Cossement C; Lionne-Huyghe P; Rose C; Bauters F; Preudhomme C
Leukemia; 2006 Nov; 20(11):2067-70. PubMed ID: 16990759
[No Abstract] [Full Text] [Related]
36. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Malcovati L; Della Porta MG; Pietra D; Boveri E; Pellagatti A; Gallì A; Travaglino E; Brisci A; Rumi E; Passamonti F; Invernizzi R; Cremonesi L; Boultwood J; Wainscoat JS; Hellström-Lindberg E; Cazzola M
Blood; 2009 Oct; 114(17):3538-45. PubMed ID: 19692701
[TBL] [Abstract][Full Text] [Related]
37. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
38. The role of JAK2 mutations in RARS and other MDS.
Hellström-Lindberg E; Cazzola M
Hematology Am Soc Hematol Educ Program; 2008; ():52-9. PubMed ID: 19074058
[TBL] [Abstract][Full Text] [Related]
39. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: case report and literature review.
Găman M; Vlădăreanu AM; Onisai M
Rom J Morphol Embryol; 2012; 53(3):645-50. PubMed ID: 22990561
[TBL] [Abstract][Full Text] [Related]
40. TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms.
Soyer N; Tezcanlı Kaymaz B; Cömert Özkan M; Aktan Ç; Küçükaslan AŞ; Şahin F; Kosova B; Saydam G
Turk J Haematol; 2017 Jun; 34(2):174-178. PubMed ID: 28218607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
